AOCCN2017

Presentation information

Poster Presentation

[P1-1~141] Poster Presentation 1

Thu. May 11, 2017 9:30 AM - 4:00 PM Poster Room A (1F Navis A.B.C)

[P1-14] Efficacy of aripiprazole versus haloperidol for schizophrenia and schizoaffective disorder: a meta-analysis

Zhaoxia LI (Department of Pediatrics, the Second Hospital of Shandong University, China)

[Introduction] Aripiprazole and haloperidol were compared with respect to efficacy and tolerability for treating schizophrenia and schizoaffective disorder.
[Methodology] A literature review of comparisons of aripiprazole versus haloperidol for patients with schizophrenia and schizoaffective disorder was performed using Pubmed and Embase and 5 randomized controlled trials (RCT) were found.
[Results] All five RCTs met inclusion criteria and the relative risk (RR) and 95% confidence interval (CI) of aripiprazole versus haloperidol for patients who discontinued therapy were 0.92 (0.84-1.01). The positive and negative syndrome scale (PANSS) ≥20% reduction and PANSS ≥30% reduction were 1.04 (0.93-1.15) and 1.13 (0.98-1.30), respectively. RR and 95% CI for occurrence of akathisia, insomnia, extrapyramidal syndrome, the need for anticholinergic medication for extrapyramidal symptoms-related adverse events (EPS-related AEs), weight gain and increased prolactin were 0.57 (0.47-0.69), 1.03 (0.87-1.21), 0.41 (0.34-0.50), 0.49 (0.43-0.56), 1.09 (0.75-1.57), 0.09 (0.07-0.11), respectively.
[Conclusions] Patients discontinued either drug at similar rates but haloperidol caused akathisia, extrapyramidal syndrome, the need for anticholinergic medication for EPS-related AEs, and increased prolactin more frequently than aripiprazole.